TMEM106B and progressive supranuclear palsy: Figure 5 compares mRNA expression levels of TMEM106B between cognitively unimpaired individuals (CU) and individuals with progressive supranuclear palsy (PSP), pathological aging (PA) and Alzheimer’s disease (AD) from the Mayo clinic cohort.